6-MAPDB: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
 
Line 1: Line 1:
{{Short description|Overview of the chemical compound 6-MAPDB}}
== 6-MAPDB ==
{{Drugbox
| verifiedfields = changed
| verifiedrevid = 477002123
| IUPAC_name = 1-(2,3-dihydro-1H-inden-5-yl)-2-(methylamino)propan-1-one
| image = 6-MAPDB_structure.png
| image_size = 200px
| legal_status = Uncontrolled
| routes_of_administration = Oral
| CAS_number = 1354631-79-0
| PubChem = 71308120
| ChemSpiderID = 29341882
| C=13
| H=17
| N=1
| O=1
| smiles = CC(C(=O)C1=CC2=C(C=C1)CCC2)NC
}}


'''6-MAPDB''' (6-Methylaminopropylbenzodioxolylbutanone) is a synthetic [[empathogen]] and [[stimulant]] of the [[substituted cathinone]] class. It is structurally related to [[6-APDB]] and [[6-MAPB]], which are known for their [[entactogenic]] effects.
[[File:6-MAPDB_structure.png|thumb|right|Chemical structure of 6-MAPDB]]


==Chemical structure==
'''6-MAPDB''' is a synthetic compound that belongs to the class of [[phenethylamines]]. It is structurally related to other compounds in the [[benzodioxole]] family, which are known for their psychoactive properties. 6-MAPDB is of interest in the field of [[neuropharmacology]] due to its potential effects on the [[central nervous system]].
6-MAPDB is a derivative of the [[cathinone]] class, characterized by the presence of a [[ketone]] group at the beta position of the [[amine]] chain. The compound features a [[methylamino]] group attached to the [[alpha carbon]] and a [[dihydrobenzofuran]] moiety, which is a common feature in many [[entactogens]].


==Pharmacology==
=== Chemical Structure ===
6-MAPDB acts primarily as a [[serotonin]] and [[dopamine]] releasing agent. It is believed to exert its effects by increasing the levels of these neurotransmitters in the [[synaptic cleft]], leading to enhanced mood and increased energy levels. The compound's action on the [[serotonin transporter]] is thought to be responsible for its empathogenic properties.
6-MAPDB, or 6-(2-methylaminopropyl)-2,3-dihydrobenzofuran, is characterized by its [[benzofuran]] core structure. The presence of a [[methylamino]] group at the 2-position of the propyl chain is a key feature that influences its pharmacological activity. The [[chemical structure]] of 6-MAPDB is similar to that of other [[entactogens]] and [[empathogens]], which are known to affect [[serotonin]] release and reuptake.


==Effects==
=== Pharmacology ===
The effects of 6-MAPDB are similar to those of other [[entactogens]] and [[stimulants]]. Users report feelings of [[euphoria]], increased [[empathy]], and heightened [[sensory perception]]. The stimulant effects include increased [[alertness]] and [[energy]]. However, the safety profile and potential for [[neurotoxicity]] of 6-MAPDB are not well-studied.
6-MAPDB is believed to act primarily as a [[serotonin releasing agent]] (SRA), similar to other compounds in its class. This action is thought to be responsible for its potential [[psychoactive]] effects, which may include altered [[mood]], [[perception]], and [[cognition]]. The exact [[mechanism of action]] of 6-MAPDB is not fully understood, and research is ongoing to elucidate its effects on the [[brain]].


==Legal status==
=== Potential Uses ===
As of the current date, 6-MAPDB is not specifically controlled under international drug laws. However, it may be subject to [[analogue laws]] in certain jurisdictions, which regulate substances based on their structural similarity to controlled drugs.
While 6-MAPDB is not approved for any medical use, it is studied for its potential applications in [[psychotherapy]] and [[psychiatry]]. Compounds with similar structures have been investigated for their ability to enhance [[empathy]] and [[emotional processing]], which could be beneficial in therapeutic settings.


==Related compounds==
=== Legal Status ===
* [[6-APDB]]
The legal status of 6-MAPDB varies by country. In some jurisdictions, it is classified as a [[controlled substance]] due to its structural similarity to other psychoactive compounds. Researchers must adhere to strict regulations when studying 6-MAPDB to ensure compliance with local laws.
* [[6-MAPB]]
* [[MDMA]]
* [[MDA]]


==See also==
== Related Pages ==
* [[Substituted cathinone]]
* [[Phenethylamine]]
* [[Entactogen]]
* [[Benzodioxole]]
* [[Serotonin releasing agent]]
* [[Psychoactive drug]]
* [[Psychoactive drug]]


==Related pages==
[[Category:Phenethylamines]]
* [[List of entactogens]]
[[Category:Psychoactive drugs]]
* [[List of substituted cathinones]]
 
[[Category:Substituted cathinones]]
[[Category:Entactogens and empathogens]]
[[Category:Stimulants]]

Latest revision as of 03:40, 13 February 2025

6-MAPDB[edit]

Chemical structure of 6-MAPDB

6-MAPDB is a synthetic compound that belongs to the class of phenethylamines. It is structurally related to other compounds in the benzodioxole family, which are known for their psychoactive properties. 6-MAPDB is of interest in the field of neuropharmacology due to its potential effects on the central nervous system.

Chemical Structure[edit]

6-MAPDB, or 6-(2-methylaminopropyl)-2,3-dihydrobenzofuran, is characterized by its benzofuran core structure. The presence of a methylamino group at the 2-position of the propyl chain is a key feature that influences its pharmacological activity. The chemical structure of 6-MAPDB is similar to that of other entactogens and empathogens, which are known to affect serotonin release and reuptake.

Pharmacology[edit]

6-MAPDB is believed to act primarily as a serotonin releasing agent (SRA), similar to other compounds in its class. This action is thought to be responsible for its potential psychoactive effects, which may include altered mood, perception, and cognition. The exact mechanism of action of 6-MAPDB is not fully understood, and research is ongoing to elucidate its effects on the brain.

Potential Uses[edit]

While 6-MAPDB is not approved for any medical use, it is studied for its potential applications in psychotherapy and psychiatry. Compounds with similar structures have been investigated for their ability to enhance empathy and emotional processing, which could be beneficial in therapeutic settings.

Legal Status[edit]

The legal status of 6-MAPDB varies by country. In some jurisdictions, it is classified as a controlled substance due to its structural similarity to other psychoactive compounds. Researchers must adhere to strict regulations when studying 6-MAPDB to ensure compliance with local laws.

Related Pages[edit]

Retrieved from "https://wikimd.com/index.php?title=6-MAPDB&oldid=6290797"